BACKGROUND: The decreased immune response among elderly individuals results in reduced influenza vaccine efficacy. Strategies to improve vaccine efficacy in elderly individuals are needed. The goal of this study was to determine whether a cationic lipid/DNA complex (CLDC) can improve the efficacy of the trivalent inactivated influenza vaccine Fluzone in elderly nonhuman primates. METHODS: Elderly (age, >18 years) rhesus macaques were vaccinated with Fluzone, with or without CLDC, and challenged with a human seasonal influenza virus isolate, A/Memphis/7/2001(H1N1). RESULTS: We found that elderly macaques have significantly lower levels of circulating naive CD4(+) T cells, naive CD8(+) T cells, and B cells as compared to juvenile monkeys. Furthermore, on the day of challenge, recipients of Fluzone/CLDC had significantly higher plasma anti-influenza virus immunoglobulin G (P < .001) and immunoglobulin A (P < .001) titers than recipients of Fluzone alone. After virus challenge, only the Fluzone/CLDC-vaccinated animals had a significantly lower level of virus replication (P < .01) relative to the unvaccinated control animals. CONCLUSIONS: These results demonstrate that CLDC can enhance the immunogenicity and efficacy of a licensed TIV in immunosenescent elderly monkeys.
BACKGROUND: The decreased immune response among elderly individuals results in reduced influenza vaccine efficacy. Strategies to improve vaccine efficacy in elderly individuals are needed. The goal of this study was to determine whether a cationic lipid/DNA complex (CLDC) can improve the efficacy of the trivalent inactivated influenza vaccine Fluzone in elderly nonhuman primates. METHODS: Elderly (age, >18 years) rhesus macaques were vaccinated with Fluzone, with or without CLDC, and challenged with a human seasonal influenza virus isolate, A/Memphis/7/2001(H1N1). RESULTS: We found that elderly macaques have significantly lower levels of circulating naive CD4(+) T cells, naive CD8(+) T cells, and B cells as compared to juvenile monkeys. Furthermore, on the day of challenge, recipients of Fluzone/CLDC had significantly higher plasma anti-influenza virus immunoglobulin G (P < .001) and immunoglobulin A (P < .001) titers than recipients of Fluzone alone. After virus challenge, only the Fluzone/CLDC-vaccinated animals had a significantly lower level of virus replication (P < .01) relative to the unvaccinated control animals. CONCLUSIONS: These results demonstrate that CLDC can enhance the immunogenicity and efficacy of a licensed TIV in immunosenescent elderly monkeys.
Authors: Robert B Couch; Patricia Winokur; Rebecca Brady; Robert Belshe; Wilbur H Chen; Thomas R Cate; Bryndis Sigurdardottir; Amy Hoeper; Irene L Graham; Robert Edelman; Fenhua He; Diane Nino; Jose Capellan; Frederick L Ruben Journal: Vaccine Date: 2007-09-14 Impact factor: 3.641
Authors: David K Hong; Stella Chang; Crystal M Botham; Thierry D Giffon; Jeffery Fairman; David B Lewis Journal: J Virol Date: 2010-10-13 Impact factor: 5.103
Authors: William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Carolyn B Bridges; Nancy J Cox; Keiji Fukuda Journal: JAMA Date: 2004-09-15 Impact factor: 56.272
Authors: Timothy D Carroll; Shannon R Matzinger; Meritxell Genescà; Linda Fritts; Roxana Colòn; Michael B McChesney; Christopher J Miller Journal: J Immunol Date: 2008-02-15 Impact factor: 5.422
Authors: Timothy D Carroll; Sinthujan Jegaskanda; Shannon R Matzinger; Linda Fritts; Michael B McChesney; Stephen J Kent; Jeffery Fairman; Christopher J Miller Journal: J Infect Dis Date: 2018-08-14 Impact factor: 5.226
Authors: Tania Rivera-Hernandez; Diane G Carnathan; Peter M Moyle; Istvan Toth; Nicholas P West; Paul R Young; Guido Silvestri; Mark J Walker Journal: Discov Med Date: 2014-12 Impact factor: 2.970
Authors: Ana Mosterín Höpping; Janet McElhaney; Judith M Fonville; Douglas C Powers; Walter E P Beyer; Derek J Smith Journal: Vaccine Date: 2015-12-05 Impact factor: 3.641
Authors: Hayden N Brochu; Elizabeth Tseng; Elise Smith; Matthew J Thomas; Aiden M Jones; Kayleigh R Diveley; Lynn Law; Scott G Hansen; Louis J Picker; Michael Gale; Xinxia Peng Journal: J Immunol Date: 2020-05-06 Impact factor: 5.422
Authors: Anna Stachyra; Monika Rak; Patrycja Redkiewicz; Zbigniew Madeja; Katarzyna Gawarecka; Tadeusz Chojnacki; Ewa Świeżewska; Marek Masnyk; Marek Chmielewski; Agnieszka Sirko; Anna Góra-Sochacka Journal: Virol J Date: 2017-09-02 Impact factor: 4.099